Literature DB >> 18162247

A new challenge for Europe: introducing a pediatric quadrivalent vaccine for measles, mumps, rubella, and varicella.

José Ramet1.   

Abstract

BACKGROUND: Varicella is often considered to be a benign disease of childhood. In fact, varicella is associated with serious complications and mortality even among healthy individuals. DISCUSSION: Although the course of varicella can be uncomplicated, it can also be associated with serious complications such as pneumonia, fluid and electrolyte disturbances, skin and soft tissue infections and central nervous system disturbances. Worldwide studies have confirmed the high frequency of disease as well as the resultant morbidity, mortality and medical resource use. A quadrivalent vaccine is now available in certain countries to protect against measles, mumps, rubella and varicella (MMRV). Countries that have initiated routine vaccination pro- grams have reported substantial reductions in morbidity and mortality as well as improved health outcomes. The MMRV vaccine facilitates coverage against all four diseases, and would be expected to improve compliance as well as coverage of varicella.
CONCLUSIONS: Universal vaccination programs with MMRV should be considered as a way to reduce the medical and economic impact of varicella. The MMRV vaccine provides a means to achieve universal coverage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18162247     DOI: 10.1016/S1201-9712(07)60022-8

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  3 in total

1.  Measles-mumps-rubella-varicella combination vaccine (ProQuad): a guide to its use in children in the E.U.

Authors:  Lesley J Scott
Journal:  Paediatr Drugs       Date:  2015-04       Impact factor: 3.930

2.  How did the adoption of wP-pentavalent affect the global paediatric vaccine coverage rate? A multicountry panel data analysis.

Authors:  M Mahmud Khan; Juan Camilo Vargas-Zambrano; Laurent Coudeville
Journal:  BMJ Open       Date:  2022-04-04       Impact factor: 2.692

3.  Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries.

Authors:  Piero Poletti; Alessia Melegaro; Marco Ajelli; Emanuele Del Fava; Giorgio Guzzetta; Luca Faustini; Giampaolo Scalia Tomba; Pierluigi Lopalco; Caterina Rizzo; Stefano Merler; Piero Manfredi
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.